Development of Polymeric Microparticles for the Delivery of Oral Vaccine
Article Sidebar
Main Article Content
Abstract
The object of this study was to develop microparticles from poly (D,L-lactic-co-glycolic acid) (PLGA) using solvent evaporation method for oral vaccine delivery. The PLGA microparticles were coated with chitosan that varying molecular weight (50000, 100000, 200000), concentration (0.25%, 0.5%, 1.0%, 1.5%, 2% w/w), Cetyltrimethylammonium bromide (CTAB) 1.0% w/w and mixture of chitosan and CTAB in the ratio of 1:1. The obtained microparticles had average size in the range of 1.517 to 5.077 micrometers. Microscopic images from scanning electron microscope showed spherical shape with smooth surface. The microparticles had positive surface charge (10.4-66.4 mV) and could adsorb Ovalbumin (OVA) about 32.3-75.0% w/w. The 1% w/w CTAB-coated microparticles showed the highest OVA-loading. In conclusion, the developed microparticles by coating with these cationic agents showed the optimum size which was smaller than 10 micrometers and the positive surface charge, resulting in the higher protein adsorption. These microparticles possibly act as the appropriate protein delivery system targeting to peyerûs patches of small intestine for oral vaccine.
Article Details
In the case that some parts are used by others The author must Confirm that obtaining permission to use some of the original authors. And must attach evidence That the permission has been included
References
Almeida AJ, Souto E. 2007. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 59: 478-490.
Borges O, Borchard G, Verhoef JC, et al. 2005. Preparation of coated nanoparticles for a new mucosal vaccine delivery system. Int J Pharm 299: 155-166.
Byrd W, Lorimier AD, Zheng ZR, et al. 2005. Microencapsulated subunit vaccine approach to enterotoxigenic Escherichia coli and other mucosal pathogens. Adv Drug Deliv Rev 57: 1362-1380.
Challacombe SJ, Rahman D, Jeffery H, et al. 1992. Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology 76: 164-168.
Cui F, Qian F, Yin C. 2006. Preparation and characterization of mucoadhesive polymer- coated nanoparticles. Int J Pharm 316: 154-161.
de Magistris MT. 2006. Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv Drug Deliv Rev 58: 52-67.
Illum L, Jabbal-Gill I, Hinchcliffe M. 2001. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 51: 81-96.
Italia JL, Bhatt DK, Bhardwaj V, et al. 2007. PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to Sandi mmune Neoral. J Control Release 119: 197-206.
Jung T, Kamm W, Breitenbach A, et al. 2000. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur J Pharm Biopharm 50: 147-160.
Levine MM. 2003. Can needle-free administration of vaccines become the norm in global immunization? Nat Med 9: 99-103.
Lowry OH, Rosebrough NJ, Farr AL, et al. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
Malvern Instrument Ltd. 2003. Zetasizer nano series user manual. Van der Lubben IM, Verhoef JC, Borchard G, et al. 2001. Chitosan for mucosal vaccination. Adv Drug Deliv Rev 52: 139-144.
Zuzzi S, Cametti C, Onori G, et al. 2007. Liposome- induced DNA compaction and reentrant condensation investigated by dielectric relaxation spectroscopy and dynamic light scattering techniques. Phys Rev E Stat Nonlin Soft Matter Phys 76(1): 011925.